MedTrace Logo

A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

NCT03056989 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2017-09-05

No results posted yet for this study

Summary

Ascending dose, 7-day, open label safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.

Conditions

Interventions

DRUG

SPX-101

Inhalation solution twice daily for 7 days.

Sponsors & Collaborators

  • Spyryx Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Elizabeth Tullis, MD · Unity Health Toronto

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-31
Primary Completion
2017-08-02
Completion
2017-08-02

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03056989 on ClinicalTrials.gov